Spring Health Launches Integrated Critical Incident Response to Help Companies Navigate Crisis with Confidence and Compassion
New longitudinal approach delivers real-time transparency, in-house trauma-informed providers, and ongoing support beyond the event to redefine workplace crisis care.
NEW YORK, April 29, 2025 /PRNewswire/ -- Spring Health, a complete global mental health solution for employers and health plans, has launched Integrated Critical Incident Response—a comprehensive approach to crisis response that empowers HR leaders to support their organizations with clarity and effective support when it matters most.
As critical incidents grow in frequency and visibility, HR leaders are under mounting pressure to respond with both precision and compassion. Yet most are left navigating these high-stakes moments with outdated tools, limited insight, and short-lived support. Spring Health's Integrated Critical Incident Response sets a new standard—offering the industry's first fully integrated, longitudinal solution built within a high-quality mental health platform.
Unlike traditional models, Spring Health offers a modern, tech-enabled approach to critical incident response, including:
'Most crisis response services are designed to check a box—they show up, hold a session, and disappear,' said Gijo Mathew, Chief Product Officer at Spring Health. 'We created Integrated Critical Incident Response to offer something different—a modernized approach to give HR leaders a solution they can trust, and employees the kind of support that doesn't end when the headlines fade. It's about being there for the full journey, not just the first 24 hours.'
'A single conversation after a crisis isn't enough to drive real recovery or restore a sense of safety,' said Dr. Mill Brown, Chief Medical Officer at Spring Health. 'The therapeutic process takes time, trust, and consistent support. Our model is built to provide exactly that—longitudinal care from trauma-informed experts who stay engaged well beyond the initial response. We're not just addressing the moment of crisis—we're guiding people through the full arc of recovery with compassion, structure, and clinical excellence.'
Spring Health's approach is grounded in the latest trauma science and delivers tools built for clinical impact and everyday usability. The model moves beyond one-time interventions to offer sustained care that helps employees and leaders navigate the full recovery journey. Integrated Critical Incident Response equips every individual touched by a workplace crisis with the tools they need to move forward.
Learn more by visiting our website here.
About Spring Health
Spring Health is a complete global mental health solution for employers and health plans. By integrating products for members, providers, and customers, Spring Health uniquely delivers personalized care for every individual—ranging from digital tools and meditation to coaching, therapy, and medication—ensuring the right care at the right time. Certified by JAMA Network Open and the Validation Institute for demonstrating net savings for customers, Spring Health also equips global business leaders with intelligent technology, real-time insights, and clinical expertise to support diverse and evolving organizational needs.
Today, more than 20 million people worldwide have access to Spring Health. We're trusted by leading employers, health plans and channel partners, including Adobe, Bumble, General Mills, Moda Health, Wellstar, and Guardian, to drive cultural impact at scale. For more information, please visit https://www.springhealth.com.
Media Contact
5WPR
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/spring-health-launches-integrated-critical-incident-response-to-help-companies-navigate-crisis-with-confidence-and-compassion-302440560.html
SOURCE Spring Health
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials Novavax continues to pursue partnering opportunities to advance further development of these programs GAITHERSBURG, Md., June 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial that showed both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid® and Fluzone HD, respectively. This cohort was designed to provide descriptive data on three flu strains (H1N1, H3N2, B) and SARS-CoV-2 (COVID-19) to inform a future registrational Phase 3 program. "Both our combination and stand-alone flu vaccine candidates induced robust immune responses and were well tolerated," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "This data set adds to findings from our Phase 2 trial and will help inform discussions with potential partners." Both stand-alone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline). Both vaccine candidates were well tolerated and saw reactogenicity comparable to authorized comparators. Nearly all (>98%) solicited adverse events were mild or moderate in severity. This descriptive trial was designed to evaluate the safety and immunogenicity of the CIC and stand-alone flu vaccine candidates compared to Nuvaxovid and Fluzone HD in approximately 2,000 adults aged 65 and older. This trial was not adequately powered to demonstrate statistical significance. These results build on previous Phase 2 data. About NovavaxNovavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for its CIC and stand-alone influenza vaccine to be used with a partner in a registrational Phase 3 program, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: InvestorsLuis Sanay, CFA240-268-2022ir@ MediaGiovanna Chandler202-709-5563media@ View original content to download multimedia: SOURCE Novavax, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology
ST. PAUL, Minn., June 11, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the issuance of U.S. Patent No. 12,311,173. This new patent strengthens iotaMotion's intellectual property portfolio and supports the company's mission to advance cochlear implant surgery beyond human capability. The patent covers concepts including systems for utilizing separate positioning and power components to streamline the intraoperative use of robotically controlled positioning. "This patent represents a significant milestone for iotaMotion as we continue to build out our IP portfolio and expand our technology roadmap," said Mike Lobinsky, CEO & President of iotaMotion. The announcement comes on the heels of recent NIH grant awards leveraging the core technology platform of the iotaSOFT® Insertion System: Phase I grant awarded to Qualia Oto to evaluate potential applications for robotic assistance to assist in array insertion using novel shape-changing polymers Phase I grant awarded to iotaMotion to support the development of a navigation-based cochlear implant insertion to optimize trajectory during insertion "We are proud to see our industry-leading efforts recognized through this patent. Alongside recent grant-funded initiatives, this milestone reinforces the role our technology plays in both clinical practice and advancing research to shape the future of cochlear implantation," said Costa Nikou, Chief Technology Officer at iotaMotion. iotaMotion continues to advance the field of cochlear implantation through partnerships with academic and industry collaborators. Looking ahead, cochlear implantation is expected to integrate robotic assistance with enabling technology such as navigation and electrocochleography. With hundreds of successful insertions with the iotaSOFT Insertion System completed at more than 25 centers across the United States, iotaMotion will continue to expand commercially, while innovating on its product roadmap. About iotaMotion iotaMotion, Inc. is a medical technology company based in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures. The system is commercially available in the United States and under clinical investigation in other global markets. For more information, visit or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@ View original content to download multimedia: SOURCE iotaMotion, Inc.
Associated Press
32 minutes ago
- Associated Press
Capital Rx Acquires Care Navigation Company Amino Health
With Amino Health, Capital Rx launches Judi Care, a next-generation care navigation solution that helps health plan members avoid the pitfalls of the overly complex U.S. healthcare system NEW YORK, June 11, 2025 /PRNewswire/ -- Capital Rx, Inc., the enterprise health technology company, today announced the acquisition of Amino Health and its comprehensive health navigation platform. Amino Health will become Capital Rx's care navigation solution, Judi Care, extending Capital Rx's enterprise platform capabilities to nearly 60 million covered lives across the company's portfolio. With Amino Health, Capital Rx now offers employers all the components needed to create a holistic benefits plan design and address barriers to care that impact millions of Americans.1 'Outdated technology, stale provider directories, and misaligned incentives should never encumber a patient's care journey. With Judi Care's data-first, AI-driven patient navigation solution, we are bringing our clients the level of transparency and control required to engage and empower plan members to seek the best possible care when needed,' said AJ Loiacono, Co-Founder and Chief Executive Officer, Capital Rx. 'This potent combination of Judi Health's Unified Claims Processing™ for medical and pharmacy benefits, combined with Judi Care's AI patient navigation, will deliver unparalleled care to members.' With Judi Care, plan members will have access to: 'Our goal at Amino has always been to simplify the consumer healthcare journey. By integrating provider search, appointment booking, cost estimates, and prescription savings into one seamless experience, we are empowering people to take control of their health,' said John Asalone, Chief Executive Officer of Amino Health. 'We've brought all the data together in a configurable, AI-driven platform to deliver the best navigation experience possible. Joining Capital Rx will accelerate our mission and bring the platform to millions of more members.' John Asalone will join Capital Rx as Executive Vice President of Judi Care. Judi Care, when combined withJudi Health™, the industry's first Unified Claim Processing platform, will provide health plans, third-party administrators, government agencies, and employers, including health systems, with a fully integrated solution to seamlessly manage pharmacy and medical benefits. This unique blend of technology, aggregated data, and centralized, AI-powered workflows is the future of health benefits administration and represents one of the most significant strides toward value-based care ever made. To learn more about Judi Care, please visit About Capital Rx Capital Rx is a health technology company providing comprehensive full-service health benefit solutions to carriers, health plans, TPAs, employer groups, and government entities. As a public benefit corporation, Capital Rx is executing its mission to reduce healthcare costs as a pharmacy benefit administrator and by deploying Judi®, the company's cloud-native enterprise health platform. Together with its clients, Capital Rx is reimagining the administration of benefits and rebuilding trust in the healthcare industry. To learn more, visit Media Contacts Michael Passanante, SVP, Marketing & Communications Justin Venneri, Senior Director, Communications [email protected] Alex Jenkins, 120/80 Group [email protected] 1 Beyond cost, what barriers to health care do consumers face? Peterson-KFF Health System Tracker. 08/22/2024. View original content to download multimedia: SOURCE Capital Rx
